Hydrochloride Door to Door Medetomidine Imidazole Medetomidine

• Customization: Available
• CAS No.: 86347-14-0
• Formula: C13h16n2
• Model NO.: QS-Medetomidine
• EINECS: 811-718-6
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: 2 Years
• Nutrient Composition: Medetomidine
• Resource: Medetomidine
• The content of active substances: 99%
• Product Name: Medetomidine
• Name: Medetomidine Powder
• Appearance: White Powder
• Mf: C13h16n2
• MW: 200.285
• Melting Point: 151.5 - 152.5 Deg C
• Boiling Point: 381.9 C at 760 Mmhg
• Density: 1.053
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anesthetic
• Specific: COA
• Test Method: HPLC
• Vp: 0.0±0.8 Mmhg at 25°c
• Pka: 14.29±0.10(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: QS
• Origin: Shaanxi Xi′an
• Production Capacity: 1 Ton/Month

Product Description

Hydrochloride Door to Door Medetomidine Imidazole Medetomidine

Product Description

Product Detials

Product Name	Medetomidine
Apperance	White Powder
CAS	86347-14-0
MF	C13H16N2
MW	200.285

Dexmedetomidine hydrochloride is a relatively selective α2 receptor agonist, which has sedative, anti-anxiety, hypnotic, analgesic and sympathetic nerve blocking effects. Dexmedetomidine hydrochloride was approved by the US Food and Drug Administration (FDA) in 1999 for short-term sedation of adult patients with mechanical ventilation in the intensive care unit (ICU). At present, the United States and European countries have begun to use dexmedetomidine hydrochloride in departments other than the ICU, including neurosurgery, pediatrics, cardiovascular surgery, fiberoptic bronchoscopy and obesity treatment surgery, etc.

Application&Function

Functional Classification
Pharmacologic Class: Selective α-adrenoceptor agonist (high affinity for α over α receptors).

Therapeutic Category:

Sedative (veterinary & human off-label use)

Analgesic adjunct

Anesthetic sparing agent

Key Functions
Sedation: Induces dose-dependent calmness by inhibiting CNS norepinephrine release.
Analgesia: Enhances pain relief via spinal cord α receptor activation.
Hemodynamic Effects: Initial transient hypertension (α-mediated vasoconstriction) followed by bradycardia.
Veterinary Use: Primary FDA-approved for canine/feline sedation.
Human Use: Off-label for ICU sedation (dexmedetomidine, its active enantiomer, is more commonly used).

Specification

Certificate of Analysis